AbbVie Inc (ABBV)

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

• Relazione annuale (10-K)

  Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.

  Depositato il 2026-02-20

  Vedi documento

• Relazione trimestrale (10-Q)

  Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.

  Depositato il 2026-08-03

  Vedi documento

• Comunicazione price-sensitive (8-K)

  Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.

  Depositato il 2026-09-03

  Vedi documento

• 8/4/2026NEUTRAL
  AbbVie Set to Sell $10 Billion in Bonds to Fund Apogee Deal

  AbbVie Inc. has initiated a $10 billion offering of investment-grade bonds. The proceeds are earmarked to finance the company's ongoing acquisition of Apogee Therapeutics Inc. This move signals AbbVie's commitment to expanding its portfolio through strategic M&A, utilizing debt financing to secure the deal. While the bond sale itself is a financing event, its success and the ultimate integration of Apogee will be key factors for investors to monitor regarding future growth and financial leverage.

• 8/4/2026POSITIVE
  AbbVie Sees Strong Demand for Its $10 Billion M&A Bond Sale

  AbbVie Inc. successfully priced a $10 billion investment-grade bond offering, indicating strong investor demand. This comes at a time when many investors have shown fatigue with new debt issuances aimed at funding artificial intelligence initiatives. The robust uptake of AbbVie's bonds suggests a preference for established pharmaceutical companies with solid fundamentals over speculative tech-related debt. The offering's success provides AbbVie with ample liquidity for its strategic M&A activities, potentially enhancing its long-term growth prospects and shareholder value.

• 6/26/2026POSITIVE
  Healthcare stocks have become a haven for investors ditching tech

  AbbVie Inc. is poised to reach new all-time highs, reflecting a resurgent investor interest in the biopharmaceutical sector. This trend, also seen with peers Eli Lilly and Johnson & Johnson, suggests a strategic shift by investors moving capital away from technology stocks towards healthcare. The sector's perceived stability and defensive qualities are attracting capital, potentially signaling a rotation driven by macroeconomic uncertainty or a reassessment of growth prospects across different industries. For investors, this indicates a potential opportunity in healthcare, especially in companies demonstrating strong fundamentals and innovation.

• 6/22/2026POSITIVE
  AbbVie to Buy Apogee Therapeutics for $10.9 Billion

  AbbVie Inc. is set to acquire Apogee Therapeutics for $10.9 billion, a strategic move to bolster its dermatology pipeline. The acquisition includes Apogee's promising treatments for atopic dermatitis, commonly known as eczema. This deal significantly enhances AbbVie's market position in the lucrative dermatology sector. For investors, this acquisition signals AbbVie's commitment to expanding its therapeutic offerings and driving future growth through targeted M&A activity, potentially leading to increased revenue streams and market share.

• 6/20/2026POSITIVE
  AbbVie would gain an experimental eczema drug by buying biotech: report

  AbbVie Inc. is reportedly in advanced talks to acquire a biotechnology firm for $10.9 billion in cash, seeking to bolster its pipeline with a promising experimental drug for atopic dermatitis. This strategic move aims to diversify AbbVie's revenue streams beyond its current blockbuster treatments and secure future growth in the dermatology sector. The acquisition, if successful, could significantly enhance AbbVie's market position and offer substantial long-term value to its shareholders by integrating innovative therapies into its portfolio.

• 6/11/2026POSITIVE
  AbbVie, Devon Energy And More On CNBC's 'Final Trades'

  CNBC's 'Final Trades' segment highlighted AbbVie Inc. (ABBV) as a top pick, citing its growth prospects driven by an expanded drug label. This positive outlook suggests potential for increased revenue and market share for the biopharmaceutical company. Investors may view this endorsement as a signal of strong upcoming performance, potentially leading to increased demand for ABBV shares.

• 6/5/2026POSITIVE
  AbbVie, Oracle, Apple And More On CNBC's 'Final Trades'

  Bryn Talkington has selected AbbVie Inc. as a 'Final Trade' with a price target of $232, indicating a bullish outlook for the pharmaceutical company. While other stocks like Entegris, Oracle, and Apple were also mentioned, AbbVie was specifically highlighted with a concrete target. This endorsement from a CNBC analyst suggests potential upside for investors, driven by the analyst's conviction in AbbVie's future performance and valuation.

• 3/18/2026NEGATIVE
  What's Going On With AbbVie Stock Today?

  AbbVie Inc. (NASDAQ: ABBV) shares experienced a downturn today, trading lower as a competitor announced substantial advancements in developing a treatment for plaque psoriasis. This development introduces increased competition in a key therapeutic area for AbbVie. Investors are likely reassessing AbbVie's market position and future revenue streams in light of this new competitive threat. The news suggests potential market share erosion or pricing pressure, impacting the stock's valuation.